Citation Impact
Citing Papers
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
2014
Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
2017
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Colorectal cancer statistics, 2020
2020 Standout
Cancer statistics, 2022
2022 Standout
Colorectal cancer statistics, 2023
2023 Standout
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Mir-34: A New Weapon Against Cancer?
2014
Cancer Statistics, 2021
2021 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Lung cancer in patients with idiopathic pulmonary fibrosis
2017
Invoking the power of thrombospondins: Regulation of thrombospondins expression
2014
QuPath: Open source software for digital pathology image analysis
2017 Standout
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Hepatocellular carcinoma
2018 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
The regulation of transcriptional repression in hypoxia
2017
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
Hepatocellular carcinoma
2021 Standout
microRNA and Lung Cancer
2015
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
2016
Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations
2016
Delivery technologies for cancer immunotherapy
2019 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients
2018
Extracellular matrix structure
2015 Standout
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
2015
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
2019
Idiopathic pulmonary fibrosis
2017 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers
2019 Standout
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
2018 StandoutNobel
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
2015
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
2020 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Reading, writing and erasing mRNA methylation
2019 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
2016
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis
2017
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence
2018
Hepatocellular carcinoma
2022 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Catechol Polymers for pH-Responsive, Targeted Drug Delivery to Cancer Cells
2011
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Screening for Colorectal Cancer
2016 Standout
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
2019
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
2016
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
2012
RNA-dependent RNA targeting by CRISPR-Cas9
2018 StandoutNobel
Colorectal cancer statistics, 2017
2017 Standout
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
2016
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
2018
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform
2014
Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis
2017
Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides
2020 StandoutNobel
Works of Giuseppe Bronte being referenced
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
2016
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
2014
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
2015
A headlight on liquid biopsies: a challenging tool for breast cancer management
2016
Multisciplinary management of patients with liver metastasis from colorectal cancer
2016
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
2010
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
2012
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
2016
Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
2010
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
2015
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?
2013
Germline copy number variation in theYTHDC2gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?
2014
Nintedanib in NSCLC: evidence to date and place in therapy
2016
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer
2013
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
2016
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines
2013
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
2013
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014